| Members |
targetComponentId |
| Bupivacaine hydrochloride 0.125% infusion solution 250mL bag |
Bupivacaine hydrochloride 1.25 mg/mL solution for injection |
| Bupivacaine hydrochloride 0.5%/epinephrine 50micrograms 10mL (1:200000) injection solution |
Product containing precisely bupivacaine hydrochloride 5 milligram/1 milliliter and epinephrine (as epinephrine bitartrate) 5 microgram/1 milliliter conventional release solution for injection (clinical drug) |
| Bupivacaine hydrochloride 0.75% injection |
Bupivacaine only product in parenteral dose form |
| Bupivacaine hydrochloride 0.75% injection solution ampule |
Bupivacaine only product in parenteral dose form |
| Bupivacaine hydrochloride 2.5mg/epinephrine bitartrate 5mcg injection solution vial |
Product containing only bupivacaine and epinephrine (medicinal product) |
| Bupivacaine hydrochloride 5mg/epinephrine 5mcg injection solution vial |
Product containing precisely bupivacaine hydrochloride 5 milligram/1 milliliter and epinephrine (as epinephrine bitartrate) 5 microgram/1 milliliter conventional release solution for injection (clinical drug) |
| Bupivacaine hydrochloride 7.5mg/dextrose 82.5mg injection solution vial |
Bupivacaine only product in parenteral dose form |
| Bupivacaine hydrochloride+epinephrine 0.75%/1:200000 injection |
Adrenaline (as adrenaline acid tartrate) 5 microgram/mL and bupivacaine hydrochloride 7.5 mg/mL solution for injection |
| Buprenorphine + naloxone withdrawal |
Buprenorphine and/or naloxone withdrawal |
| Buprenorphine 5microgram/hour transdermal patch |
Product containing only buprenorphine in transdermal dose form (medicinal product form) |
| Buprenorphine hydrochloride + naloxone hydrochloride |
Product containing buprenorphine and naloxone (medicinal product) |
| Buprenorphine hydrochloride 2mg + naloxone hydrochloride 0.5mg sublingual tablet |
Buprenorphine 2 mg and naloxone hydrochloride 500 microgram sublingual tablet |
| Buprenorphine hydrochloride 8mg + naloxone hydrochloride 2mg sublingual tablet |
Buprenorphine (as buprenorphine hydrochloride) 8 mg and naloxone hydrochloride 2 mg sublingual tablet |
| Bupropion hydrochloride 100mg m/r tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
| Bupropion hydrochloride 100mg prolonged-release oral tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
| Bupropion hydrochloride 200mg m/r tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
| Bupropion hydrochloride 200mg prolonged-release oral tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
| Bupropion hydrochloride 300mg m/r tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
| Bupropion hydrochloride 300mg prolonged-release oral tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
| Bupropion hydrochloride 50mg m/r tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
| Bupropion hydrochloride 50mg prolonged-release oral tablet |
Product containing only bupropion in oral dose form (medicinal product form) |
| Burkholderia |
Genus Burkholderia (organism) |
| Burkholderia cocovenenans |
Burkholderia gladioli |
| Burkholderia vandii |
Burkholderia plantarii |
| Burkitt lymphoma of lymph nodes of axilla and upper limb |
Burkitt lymphoma of lymph nodes of upper limb (disorder) |
| Burkitt lymphoma of lymph nodes of inguinal region and lower limb |
Burkitt lymphoma of lymph nodes of lower limb (disorder) |
| Burkitt's tumor of extranodal AND/OR solid organ site |
Burkitt's lymphoma (clinical) |
| Burkitt's tumor of lymph nodes of axilla AND/OR upper limb |
Burkitt lymphoma of lymph nodes of upper limb (disorder) |
| Burkitt's tumor of lymph nodes of inguinal region AND/OR lower limb |
Burkitt lymphoma of lymph nodes of lower limb (disorder) |
| Burn involving 10-14 percent of body surface, with 10-14 percent of body surface with full thickness burn |
Burn involving 10-19 percent of body surface, with 10-14 percent of body surface with full thickness burn (disorder) |
| Burn involving 15-19 percent of body surface, with 10-19 percent of body surface with full thickness burn |
Burn involving 10-19 percent of body surface, with 15-19 percent of body surface with full thickness burn (disorder) |
| Burn of larynx, trachea AND/OR lung |
Burn |
| Burn of other internal organ, NEC |
Burn of internal organ |
| Burn to cornea - erythema |
Corneal burn |
| Burn to cornea - erythema |
Corneal burn |
| Buserelin 150micrograms spray |
Buserelin only product |
| Buspirone hydrochloride 5mg tablet |
Buspirone hydrochloride 5 mg oral tablet |
| Buspirone hydrochlorine |
Buspirone hydrochloride (substance) |
| Butabarbital sodium 30mg/5mL elixir |
Product containing precisely secbutabarbital sodium 6 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Butorphanol tartrate 1mg/mL injection solution ampule |
Butorphanol tartrate 1 mg/mL solution for injection |
| Butorphanol tartrate 2mg/mL injection solution ampule |
Butorphanol only product in parenteral dose form |
| Buttock random pattern flap |
Random pattern flap |
| Butyl nitrate - non-pharmaceutical |
Butyl nitrate |
| Butyrophenone derivative antipsychotic agent |
Butyrophenone derivative |
| Butyrophenone poisoning NOS |
Poisoning by butyrophenone-based tranquilizer |
| Bypass of organ NOC |
Construction of shunt |
| Byrd respirator therapy |
Respiratory therapy |
| C/O - specified symptom findings |
Finding reported by subject or history provider (finding) |
| C1 esterase inhibitor 500 units powder for injection solution 8mL vial |
Product containing precisely human C1 esterase inhibitor 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| CDC Corynebacterium group G-1 |
Corynebacterium accolens |
| CDC group DF-2 |
Capnocytophaga canimorsus |
| CDE genotype |
CDE haplotype (finding) |
| CDe genotype |
CDe haplotype (finding) |
| CTV3 ROOT |
SNOMED CT Concept |
| Cabbage - dietary |
Cabbage (substance) |
| Cabergoline [parkinsons] |
Product containing cabergoline (medicinal product) |
| Caesarean delivery - delivered |
Deliveries by caesarean |
| Caffeine and sodium benzoate injection |
Product containing caffeine and sodium benzoate (medicinal product) |
| Caffeine containing substance - non-pharmaceutical |
Caffeine |
| Café-au-lait spots and ring chromosome 11 |
Ring chromosome 11 syndrome |
| Calcipotriene 0.005%/betamethasone 0.064% topical suspension |
Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 milliliter and calcipotriol 50 microgram/1 milliliter conventional release cutaneous lotion (clinical drug) |
| Calcitonin, salmon 100unit/mL injection solution 1mL vial |
Product containing precisely salmon calcitonin 100 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Calcitonin, salmon 200iu/mL spray |
Product containing precisely salmon calcitonin 200 unit/1 actuation conventional release nasal spray (clinical drug) |
| Calcitonin, salmon 200unt/mL injection |
Salmon calcitonin 200 unit/mL solution for injection |
| Calcitonin, salmon 200unt/mL injection solution 2mL vial |
Salmon calcitonin 200 unit/mL solution for injection |
| Calcium analyte |
Calcium |
| Calcium antacid |
Calcium compound |
| Calcium carbonate+cholecalciferol 1.25g/11micrograms/sachet granules |
Calcium carbonate 6.25 mg/mL and colecalciferol 2.2 unit/mL oral solution |
| Calcium chloride 10% injection solution 10mL prefilled syringe |
Product containing precisely calcium chloride 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Calcium hydroxyapatite microsphere suspension in aqueous based carrier 0.3mL prefilled syringe |
Hydroxyapatite only product in parenteral dose form |
| Calcium hydroxyapatite microsphere suspension in aqueous based carrier 1.3mL prefilled syringe |
Hydroxyapatite only product in parenteral dose form |
| Calcium phosphate+colecalciferol 3100mg/20micrograms/sachet powder for oral suspension |
Calcium phosphate and colecalciferol only product |
| Calculus - composition |
Calculus chemical composition - finding |
| Calculus exam. general |
Calculus examination |
| Calculus examination NOS |
Calculus examination |
| Calculus examination NOS |
Calculus examination |
| Calculus examination general |
Calculus examination |
| Calculus gen. exam. NOS |
Calculus examination |
| Calculus general examination NOS |
Calculus examination |
| Calculus of bile duct with acute cholecystitis without obstruction |
Bile duct calculus with acute cholecystitis |
| Calculus of bile duct with chronic cholecystitis without obstruction |
Calculus of bile duct with chronic cholecystitis |
| Calculus of bile duct without obstruction |
Calculus of bile duct |
| Calculus of common bile duct with acute cholecystitis without obstruction |
Calculus of common bile duct with acute cholecystitis |
| Calculus of common bile duct with chronic cholecystitis without obstruction |
Calculus of common bile duct with chronic cholecystitis (disorder) |
| Calculus of common bile duct without obstruction |
Common bile duct calculus |
| Calculus of common duct without obstruction |
Common bile duct calculus |
| Calfactant intratracheal suspension 6mL vial |
Product containing only calfactant (medicinal product) |
| Calicivirus group |
Family Caliciviridae (organism) |
| Calliphora erythrocephala |
Calliphora vicina |
| Callitrogae |
Genus Cochliomyia (organism) |
| Caloric intake, function (observable entity) |
Energy intake (observable entity) |
| Caloscypha fulgens |
Caloscypha fulgens (organism) |
| Calymmatobacterium granulomatis |
Klebsiella granulomatis (organism) |
| Camouflaging preparations adverse reaction |
Adverse reaction (disorder) |
| Campylobacter cinaedi |
Helicobacter cinaedi |
| Campylobacter fennelliae |
Helicobacter fennelliae |
| Campylobacter laridis |
Campylobacter lari |
| Campylobacter laridis rRNA |
Campylobacter lari rRNA |
| Campylobacter laridis rRNA assay |
Campylobacter lari rRNA assay |
| Campylobacter nitrofigilis |
Arcobacter nitrofigilis (organism) |
| Canakinumab 150mg powder for injection solution |
Canakinumab only product |
FHIR